Research of DIP grouping of malignant tumor chemotherapy patients based on a decision tree model
10.3760/cma.j.cn111325-20240515-00393
- VernacularTitle:基于决策树模型的恶性肿瘤化疗患者DIP分组研究
- Author:
Yun WU
1
;
Zhen REN
;
Yi ZHU
;
Fudi SU
;
Yiqi XIN
Author Information
1. 中山大学孙逸仙纪念医院医疗保险办公室，广州 510120
- Publication Type:Journal Article
- Keywords:
Malignant tumor;
Chemotherapy;
Diagnosis-intervention packet;
Decision tree model;
Chi squared automatic interaction detection
- From:
Chinese Journal of Hospital Administration
2025;41(3):223-228
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the grouping and standard cost of malignant tumors chemotherapy patients under the diagnosis-intervention packet (DIP) system based on the decision tree model, for references for optimizing the detailed grouping scheme of this disease.Methods:The data of the first page of medical records of malignant tumors chemotherapy patients in a tertiary hospital in 2022 were collected. Univariate analysis and multiple linear regression were used to analyze the influencing factors of patients′ hospitalization expenses. The Chi squared automatic interaction detection was used to construct the decision tree model to obtain the case grouping scheme and its standard expenses. The coefficient of variation and chi-square test were used to evaluate the grouping effect.Results:A total of 27 235 patients were included in this study. The number of surgical operations, length of hospital stay, gender, the number of other diagnoses, chemotherapy pathways and targeted therapy were taken as classification nodes and included in the decision tree model. A total of 13 groups were formed. The homogeneity within the groups was good(CV<0.70), and the heterogeneity between the groups was strong( χ2= 9 564.65, P<0.001). Conclusions:Based on the decision tree model, the grouping scheme for chemotherapy cases of malignant tumors was established by comprehensively considering factors such as surgical operations within the group, length of hospital stay, other diagnostic and chemotherapy pathways is relatively reasonable, which could provide references for relevant management departments to optimize the detailed grouping scheme of this disease and formulate relevant payment standards.
